Guided Therapeutics (GTHP) EBT Margin (2010 - 2025)
Guided Therapeutics (GTHP) reported EBT Margin of 206.44% for Q4 2025, up 6499356.0% on a YoY basis from N/an in Q4 2024, and up 83.31% sequentially from 1236.67% in Q3 2025.
Guided Therapeutics (GTHP) EBT Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of EBT Margin data on file, last reported at 206.44% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin rose 6499356.0% year-over-year to 206.44%; the trailing twelve-month figure through Dec 2025 stood at 416.95% (up 3411162.0% YoY), and the FY2025 full-year result was 416.69%, up 3411188.0% from the prior year.
- EBT Margin advanced to 206.44% in Q4 2025, from 1236.67% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 357.89% in Q3 2021 to a low of 65200.0% in Q4 2024.
- A 5-year average of 14300.47% and a median of 3744.32% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin plunged 6399375 bps in 2024 and soared 6499356 bps in 2025, its largest moves.
- Tracing GTHP's EBT Margin over 5 years: stood at 740.0% in 2021, then tumbled by 4864 bps to 36733.33% in 2022, then surged by 97 bps to 1206.25% in 2023, then plunged by 5305 bps to 65200.0% in 2024, then soared by 100 bps to 206.44% in 2025.
- Business Quant data shows GTHP's EBT Margin at 206.44% in Q4 2025, 1236.67% in Q3 2025, and 693.16% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -206.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -206.44% |
| Sep 30, 2025 | -1,236.67% |
| Jun 30, 2025 | -693.16% |
| Dec 31, 2024 | -65,200.00% |
| Mar 31, 2024 | -6,700.00% |
| Dec 31, 2023 | -1,206.25% |
| Jun 30, 2023 | -3,538.64% |
| Mar 31, 2023 | -3,950.00% |
| Sep 30, 2022 | -36,733.33% |
| Jun 30, 2022 | -18,520.00% |
| Mar 31, 2022 | -10,140.00% |
| Dec 31, 2021 | -740.00% |
| Sep 30, 2021 | 357.89% |
| Jun 30, 2021 | -51,700.00% |
| Dec 31, 2020 | 8,664.00% |
| Sep 30, 2020 | 2,045.45% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -266,300.00% |
| Mar 31, 2019 | -1,194.44% |